OncoCyte (NASDAQ:OCX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of OncoCyte (NASDAQ:OCX) in a research note issued to investors on Wednesday morning. The firm issued a sell rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $4.25 target price on shares of OncoCyte in a report on Wednesday, November 13th.

OncoCyte Trading Up 1.7 %

Shares of OCX stock opened at $2.37 on Wednesday. OncoCyte has a twelve month low of $1.97 and a twelve month high of $3.57. The stock has a fifty day simple moving average of $2.55 and a two-hundred day simple moving average of $2.88.

OncoCyte (NASDAQ:OCX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.54). OncoCyte had a negative return on equity of 269.32% and a negative net margin of 6,122.29%. The company had revenue of $0.12 million during the quarter. During the same period last year, the firm posted ($0.57) earnings per share. Equities research analysts predict that OncoCyte will post -2.57 earnings per share for the current fiscal year.

Insider Buying and Selling at OncoCyte

In other OncoCyte news, Director Andrew Arno acquired 12,500 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was bought at an average price of $2.11 per share, with a total value of $26,375.00. Following the completion of the transaction, the director now directly owns 81,554 shares of the company’s stock, valued at approximately $172,078.94. The trade was a 18.10 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrea S. James acquired 20,000 shares of OncoCyte stock in a transaction on Thursday, December 5th. The shares were bought at an average price of $2.29 per share, for a total transaction of $45,800.00. Following the purchase, the chief financial officer now owns 53,670 shares of the company’s stock, valued at $122,904.30. This represents a 59.40 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 122,719 shares of company stock worth $264,341. 1.58% of the stock is owned by corporate insiders.

Institutional Trading of OncoCyte

A hedge fund recently raised its stake in OncoCyte stock. Geode Capital Management LLC lifted its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 12.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 103,980 shares of the company’s stock after purchasing an additional 11,289 shares during the quarter. Geode Capital Management LLC owned about 0.62% of OncoCyte worth $296,000 as of its most recent filing with the Securities and Exchange Commission. 55.35% of the stock is currently owned by hedge funds and other institutional investors.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.